Vertex Pharmaceuticals (VRTX) to Release Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing its earnings results after the market closes on Monday, May 6th. Analysts expect Vertex Pharmaceuticals to post earnings of $3.61 per share for the quarter. Vertex Pharmaceuticals has set its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period in the prior year, the company posted $3.33 EPS. On average, analysts expect Vertex Pharmaceuticals to post $15 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $397.48 on Monday. The stock has a fifty day moving average price of $411.60 and a 200-day moving average price of $399.17. The company has a market cap of $102.73 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. Vertex Pharmaceuticals has a fifty-two week low of $320.01 and a fifty-two week high of $448.40.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock valued at $5,203,249 over the last ninety days. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VRTX. Wolfe Research began coverage on Vertex Pharmaceuticals in a report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price target for the company. Barclays upped their target price on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Robert W. Baird cut Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price for the company. in a report on Wednesday, January 31st. Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price for the company in a report on Thursday, April 11th. Finally, StockNews.com cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 20th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.